NCT07172321View on ClinicalTrials.gov

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

October 4, 2025

Study Completion Date

October 29, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

PF-08049820 MR1

Administered orally

DRUG

PF-08049820 MR2

Administered orally

DRUG

PF-08049820 IR

Administered orally

Trial Locations (1)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY